Answers are grounded in this paper and cite their sources.
Demonstrates ANDS inhibits chronic myeloid leukemia growth, suggesting new treatment paths.
Eradicating leukemic stem cells (LSCs), a major driver of primary resistance and relapse in chronic myeloid leukemia (CML) following tyrosine kinase inhibitor (TKI) treatment, is critical for achieving a cure. Previously, we identified that ANP32B promotes CML LSCs’ survival and leukemogenesis by directly binding and inhibiting p53 activity, suggesting a therapeutic opportunity. Here, we show that 1-amino-8-naphthol-2,4-disulfonic acid (ANDS) binds unacetylated p53 and restores p53 activity by disrupting ANP32B-p53 interaction. Consequently, ANDS inhibits CML cell proliferation, impairs LSC function and prolongs survival in the CML mouse model while sparing normal progenitor cells. Based on notion that ANDS, as a previously-identified CaMKP inhibitor, potentially activates p-CaMKIIγ to accelerate CML progression, we find that ANDS combination with KN93, a p-CaMKIIγ inhibitor, synergistically suppresses both TKI-sensitive and -resistant CML. Thus, we highlight that ANDS alone or in combination with CaMKP inhibitor could become a therapeutic strategy for eradicating LSCs and overcoming TKI-resistance in CML. It has been reported that p53 activity is inhibited by the Acidic nuclear phosphoprotein 32B (ANP32B) in chronic myeloid leukemia (CML). Here, the authors show that the disulfonic acid ANDS disrupts ANP32B-p53 interaction suppressing CML in preclinical models.
No takes yet. Share an insight, caveat, or question.
Yu-sheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: